Responses in other cancer types such as small cell lung cancer (SCLC), squamous cell carcinoma of the head and neck (SCCHN) and cutaneous melanoma led to an accelerated all-comer approval for pembrolizumab regardless of PD-L1 status [21,22]. This evidence concerns the gene CD274 and small cell lung carcinoma.